洛铂新辅助序贯同步放化疗对局部晚期子宫颈癌患者肿瘤标志物水平、血清CD105及细胞生长因子的影响

Effects of Loplatin neoadjuvant sequential concurrent chemoradiotherapy on tumor marker levels,serum CD105 and cell growth factors in patients with locally advanced cervical cancer

目的探究洛铂新辅助序贯同步放化疗应用于局部晚期子宫颈癌患者的效果。方法选取我科104例局部晚期子宫颈癌患者,以随机数字表法分组。对照组52例给予顺铂新辅助序贯同步放化疗,观察组52例给予洛铂新辅助序贯同步放化疗,对比两组患者临床控制率、肿瘤标志物水平、血清细胞因子及毒副反应。结果治疗后两组SCC、CEA、CYFRA21-1水平、临床控制率、毒副反应发生率无统计学意义(P>0.05);治疗后观察组CD105、VEGF、bFGF水平均低于对照组,有统计学意义(P<0.05)。结论顺铂与洛铂新辅助序贯同步放化疗局部晚期子宫颈癌患者治疗,其临床疗效相当,安全性高,但洛铂新辅助序贯同步放化疗可有效调节CD105和微血管细胞因子水平。

Objective To investigate the effect of loplatin neoadjuvant sequential concurrent chemoradiotherapy in patients with locally advanced cervical cancer.Methods 104 patients with locally advanced cervical cancer in our department were selected and grouped by random number table.Fifty-two patients in the control group received cisplatin neoadjuvant sequential chemoradiotherapy,and 52 patients in the observation group received loplatin neoadjuvant sequential chemoradiotherapy.Clinical control rate,tumor marker levels,serum cytokines and toxic and side effects were compared between the two groups.Results There was no statistical significance in SCC,CEA,CYFRA21-1 level,clinical control rate and incidence of toxic and side effects in 2 groups after treatment(P>0.05).After treatment,the levels of CD105,VEGF and bFGF in the observation group were lower than those in the control group,with statistical significance(P<0.05).Conclusion Cisplatin and Loplatin neoadjuvant sequential synchronous chemoradiotherapy have similar clinical efficacy and high safety in the treatment of locally advanced cervical cancer patients,but loplatin neoadjuvant sequential synchronous chemoradiotherapy can effectively regulate the levels of CD105 and microvascular cytokines.